SCHEMBL25188789

SCHEMBL25188789

CCCC1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.54
▸ GFER P55789 4/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ GAA P10253 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ RAD52 P43351 1/20 0.54
▸ ALDH1A1 P00352 4/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ ADRA2C P18825 1/20 0.50
▸ PTK2B Q14289 1/20 0.50
▸ ESR2 Q92731 1/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.47
▸ HTT P42858 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25192949 0.90 MAPT (0.51) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL10054726 0.86 MAPT (0.50) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL1789020 0.86 MAPT (0.58) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL156068 0.84 ADRB1 (0.47) MAPTGAAKMT2AL3MBTL1MEN1
SCHEMBL7914429 0.84 SLC6A2 (0.48) MAPTSMN1; SMN2L3MBTL1DPP4HRH3
SCHEMBL6672865 0.83 TPSAB1 (0.43) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL15650569 0.83 MAPT (0.50) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL22794821 0.83 KDM4E (0.46) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL2448590 0.83 MAPT (0.47) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL27629259 0.83 KDM4E (0.46) MAPTKDM4EGAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 — — CN disclosed
US-20230167118-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-06-01 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
CN-103911163-B Aligning agent for liquid crystal, liquid crystal orientation film and liquid crystal display cells JSR株式会社 2017-03-01 — — CN disclosed
CN-103911163-A Liquid crystal orientating agent, liquid crystal orientating film and liquid crystal display device JSR CORP 2014-07-09 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167118-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BTK, CBL, SYK MAPT 3942/4885GFER 2025/4885KDM4E 812/4885
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES AIFM2, FECH, GPX4 MAPT 4384/4885GFER 505/4885KDM4E 3495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback